Journal of Neurology

, Volume 264, Issue 4, pp 770–780 | Cite as

Neuralgic amyotrophy triggered by hepatitis E virus: a particular phenotype

  • Quentin Scanvion
  • Thierry Perez
  • François Cassim
  • Olivier Outteryck
  • Aurélia Lanteri
  • Pierre-Yves Hatron
  • Marc Lambert
  • Sandrine Morell-Dubois
Original Communication


The neuralgic amyotrophy may be of difficult diagnosis, due to phenotypic variability, with different initial presentations (upper plexus multiple mononeuropathy, lumbosacral involvement, distal reached, phrenic involvement). To date, there is little guidance on these patients’ therapeutic management, especially those for which neuralgic amyotrophy is triggered by hepatitis E virus (HEV-NA). The study aims to identify specific features that characterize patients bearing the neuralgic amyotrophy triggered by HEV. We first describe a new case report of HEV-neuralgic amyotrophy, with delayed diaphragmatic reach. Then, the literature was searched for reports of HEV-NA (n = 39), and neuralgic amyotrophy with phrenic paresis (n = 42) from 1999 to June 2016. Relevant data were retrieved, analyzed and compared with the parameters of idiopathic neuralgic amyotrophy (n = 199) of the largest cohort, described by Van Alfen and Van Engelen in 2006. Compared to the published cohort, HEV-NA patients were more likely to be men (M/F 34/5 vs. 136/63, p = 0.017), with more frequent bilateral symptoms (86.8% cases vs. 28.5%, p < 0.0001) as well as phrenic paresis (18.0 vs. 6.6%, p = 0.028). The clinical improvement is poor, with 15.6% of cases with remission only. A particular phenotype characteristic of the HEV-induced neuralgic amyotrophy has arisen. Our findings call for action in validating the above-mentioned features that illustrate the HEV-NA cases as an early diagnosis would prevent complications, especially the phrenic damage often associated with a worse functional outcome.


Brachial neuritis Parsonage–Turner syndrome Peripheral neuropathies HEV Phrenic paresis 


Author contributions

Conception and design: QS and SMD. Collection data (case report): QS, TP, FC, OO, AL, PYH, ML and SMD. Collection and assembly of data (review): QS. Data analysis: QS. Interpretation: QS and SM. Manuscript drafting: QS and SMD. Final approval of manuscript: QS, TP, FC, OO, AL, PYH, ML and SMD.


The authors thank Laura Ravasi MD-PhD. who provided medical writing services and Hélène Béhal for statistical advice on behalf of the University of Lille.

They are grateful to the National Reference Center for Hepatitis E Virus in Toulouse, France, for HEV genotype analysis.

Compliance with ethical standards

Conflicts of interest

All authors report no disclosures relevant to the manuscript.

Ethical standards

The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinski and its later amendments.



Informed consent

First and last authors had received consent from the patient whose case is reported.

Supplementary material

415_2017_8433_MOESM1_ESM.docx (83 kb)
Supplementary material 1 (DOCX 82 kb)


  1. 1.
    Van Eijk JJJ, Groothuis JT, Van Alfen N (2016) Neuralgic amyotrophy: an update on diagnosis, pathophysiology, and treatment. Muscle Nerve 53:337–350CrossRefPubMedGoogle Scholar
  2. 2.
    Van Alfen N (2011) Clinical and pathophysiological concepts of neuralgic amyotrophy. Nat Rev Neurol 7:315–322CrossRefPubMedGoogle Scholar
  3. 3.
    Van Alfen N, Van Eijk JJJ, Ennik T et al (2015) Incidence of neuralgic amyotrophy (Parsonage Turner syndrome) in a primary care setting—a prospective cohort study. PLoS ONE 10:e0128361CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Van Alfen N, Van Engelen BGM (2006) The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain 129:438–450CrossRefPubMedGoogle Scholar
  5. 5.
    Cup EH, Ijspeert J, Janssen RJ et al (2013) Residual complaints after neuralgic amyotrophy. Arch Phys Med Rehabil 94:67–73CrossRefPubMedGoogle Scholar
  6. 6.
    Dartevel A, Colombe B, Bosseray A et al (2015) Hepatitis E and neuralgic amyotrophy: five cases and review of literature. J Clin Virol 69:156–164CrossRefPubMedGoogle Scholar
  7. 7.
    Van Eijk JJJ, Madden RG, Van Der Eijk AA et al (2014) Neuralgic amyotrophy and hepatitis E virus infection. Neurology 82:498–503CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dalton HR, Webb GW, Norton BC, Woolson KL (2016) Hepatitis E virus: time to change the textbooks. Dig Dis 34:308–316CrossRefPubMedGoogle Scholar
  9. 9.
    Rose N, Lunazzi A, Dorenlor V et al (2011) High prevalence of hepatitis E virus in French domestic pigs. Comp Immunol Microbiol Infect Dis 34:419–427CrossRefPubMedGoogle Scholar
  10. 10.
    Kamar N, Marion O, Abravanel F, Izopet J, Dalton HR (2016) Extrahepatic manifestations of hepatitis E virus. Liver Int 36:467–472CrossRefPubMedGoogle Scholar
  11. 11.
    Fong F, Illahi M (2009) Neuralgic amyotrophy associated with hepatitis E virus. Clin Neurol Neurosurg 11:193–195CrossRefGoogle Scholar
  12. 12.
    Rianthavorn P, Thongmee C, Limpaphayom N, Komolmit P, Theamboonlers A, Poovorawan Y (2010) The entire genome sequence of hepatitis E virus genotype 3 isolated from a patient with neuralgic amyotrophy. Scand J Infect Dis 42:395–400CrossRefPubMedGoogle Scholar
  13. 13.
    Kamar N, Bendall RP, Peron JM et al (2011) Hepatitis E virus and neurologic disorders. Emerg Infect Dis 17:173–179CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Carli P, Landais C, Poisnel E et al (2012) Le syndrome d’Aesculape. Rev Méd Interne 33:111–114CrossRefPubMedGoogle Scholar
  15. 15.
    Inghilleri ML, Grini Mazouzi M, Juntas Morales R (2012) Neuralgic amyotrophy as a manifestation of hepatitis E infection. Rev Neurol (Paris) 168:383–384CrossRefGoogle Scholar
  16. 16.
    Cheung MCM, Maguire J, Carey I, Wendon J, Agarwal K (2012) Hepatitis E—an unexpected problem at home. Scand J Gastroenterol 47:253CrossRefPubMedGoogle Scholar
  17. 17.
    Peri AM, Milazzo L, Meroni L, Antinori S (2013) Radiculoneuropathy associated with acute hepatitis E. Dig Liver Dis 45:963–964CrossRefPubMedGoogle Scholar
  18. 18.
    Deroux A, Belbézier A, Hyerle L et al (2013) Hépatite E et troubles neurologiques: une association à ne pas méconnaître ! Rev Méd Interne 34(suppl2):A59–A60CrossRefGoogle Scholar
  19. 19.
    Valence M, Cador B, Jezequel C, Pinel JF, Jego P (2014) Syndrome de Parsonage et Turner et hépatite E: un nouveau cas. Rev Méd Interne 35(suppl2):A124–A125CrossRefGoogle Scholar
  20. 20.
    Chirio D, Demonchy E, Laffon M et al (2014) Syndrome de Parsonage Turner et hépatite E: à propos de deux cas. Rev Méd Interne 235(suppl2):A124–A124CrossRefGoogle Scholar
  21. 21.
    Motte A, Franques J, Weitten T, Colson P (2014) Hepatitis E-associated Parsonage–Turner syndrome, France. Clin Res Hepatol Gastroenterol 38:e11–e14CrossRefPubMedGoogle Scholar
  22. 22.
    Moisset X, Vitello N, Bicilli E, et al (2014) Case report: Severe bilateral amyotrophic neuralgia associated with major dysphagia secondary to acute hepatitis E. F1000ResGoogle Scholar
  23. 23.
    Deroux A, Brion JP, Hyerle L et al (2014) Association between hepatitis E and neurological disorders: two case studies and literature review. J Clin Virol 60:60–62CrossRefPubMedGoogle Scholar
  24. 24.
    Woolson KL, Forbes A, Vine L et al (2014) Extra-hepatic manifestations of autochthonous hepatitis E infection. Aliment Pharmacol Ther 40:1282–1291CrossRefPubMedGoogle Scholar
  25. 25.
    Theochari E, Vincent-Smith L, Ellis C (2015) Neuralgic amyotrophy complicating acute hepatitis E infection: a rare association. BMJ Case Rep 2015:bcr2014207669CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Décard BF, Grimm A, Andelova M et al (2015) Hepatitis-E virus associated neuralgic amyotrophy with sustained plexus brachialis swelling visualized by high-resolution ultrasound. J Neurol Sci 351:208–210CrossRefPubMedGoogle Scholar
  27. 27.
    Frezel N, Cassim F, Derambure P, Bocquillon P (2015) syndrome de Parsonage–Turner: diagnostic topographique. Pratique Neurologique-FMC 6:212–217CrossRefGoogle Scholar
  28. 28.
    Blasco Perrin H, Cintas P, Abravanel F et al (2015) Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E. Emerg Infect Dis 21:1928–1934PubMedPubMedCentralGoogle Scholar
  29. 29.
    Avila JD, Lacomis D, Lam E (2015) Neuralgic amyotrophy with phrenic neuropathy associated with hepatitis E virus infection. Muscle Nerve 52(suppl):S47–S47Google Scholar
  30. 30.
    Martínez Rodríguez L, Carvajal P, Morís G (2015) Neuralgic amyotrophy associated to hepatitis E virus infection. Med Clín 145:462–463CrossRefGoogle Scholar
  31. 31.
    Silva M, Wicki B, Tsouni P et al (2016) Hepatitis E virus infection as a direct cause of neuralgic amyotrophy. Muscle Nerve 54:325–327CrossRefPubMedGoogle Scholar
  32. 32.
    Bisciglia M, Van den Bergh P, Duprez T, Kabamba BM, Ivanoiu A (2016) Neuralgic amyotrophy associated with hepatitis E virus (HEV) infection: a case report. Acta Neurol Belg 1–3Google Scholar
  33. 33.
    Drave SA, Debing Y, Walter S et al (2016) Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells. J Viral Hepat 23:512–521CrossRefPubMedGoogle Scholar
  34. 34.
    Cruz-Martínez A, Barrio M, Arpa J (2002) Neuralgic amyotrophy: variable expression in 40 patients. J Peripher Nerv Syst 7:198–204CrossRefPubMedGoogle Scholar
  35. 35.
    Hughes PD, Polkey MI, Moxham J, Green M (1999) Long-term recovery of diaphragm strength in neuralgic amyotrophy. Eur Respir J 13:379–384CrossRefPubMedGoogle Scholar
  36. 36.
    Podnar S (2014) Nosology of idiopathic phrenic neuropathies. J Neurol 262:558–562CrossRefPubMedGoogle Scholar
  37. 37.
    Mengel AM, Stenzel W, Meisel A, Büning C (2016) Hepatitis E–induced severe myositis. Muscle Nerve 53:317–320CrossRefPubMedGoogle Scholar
  38. 38.
    Tsairis P, Dyck PJ, Mulder DW (1972) Natural history of brachial plexus neuropathy. Report on 99 patients. Arch Neurol 27:109–117CrossRefPubMedGoogle Scholar
  39. 39.
    Van Eijk JJJ, Van Alfen N, Berrevoets M, Van der Wilt GJ, Pillen S, Van Engelen BGM (2009) Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study. J Neurol Neurosurg Psychiatry 80:1120–1124CrossRefPubMedGoogle Scholar
  40. 40.
    Pischke S, Hardtke S, Bode U et al (2013) Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int 33:722–726CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Quentin Scanvion
    • 1
  • Thierry Perez
    • 2
  • François Cassim
    • 3
  • Olivier Outteryck
    • 4
  • Aurélia Lanteri
    • 1
  • Pierre-Yves Hatron
    • 1
  • Marc Lambert
    • 1
  • Sandrine Morell-Dubois
    • 1
  1. 1.Internal Medicine Department, National Reference Center for Rare Autoimmune Systemic Diseases, FHU IMMINeNT, Medical School Henri WarembourgLille University HospitalLilleFrance
  2. 2.Pneumology Department, Medical School Henri WarembourgLille University HospitalLilleFrance
  3. 3.Neurophysiology Department, Medical School Henri WarembourgLille University HospitalLilleFrance
  4. 4.Neurology Department, Medical School Henri WarembourgLille University HospitalLilleFrance

Personalised recommendations